Oppenheimer Maintains Outperform on United Therapeutics, Raises Price Target to $400
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on United Therapeutics (NASDAQ:UTHR) and raises the price target from $375 to $400.
May 02, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Hartaj Singh has maintained an Outperform rating on United Therapeutics and increased the price target from $375 to $400.
The increase in price target by a reputable analyst like Hartaj Singh suggests a strong confidence in United Therapeutics' future performance. This is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100